SOUTH EASTON, Mass., Aug. 6 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI" or "the Company") today announced the market release of its pressure cycling technology ("PCT")-enhanced trypsin digestion application for proteomics, a major new addition to its PCT family of products. Named "Proteolysis (Trypsin)-PrEP", this new PCT-enhanced processing ("PrEP") application was unveiled at the Drug Discovery & Development of Innovative Therapeutics Expo 2008, being held this week at the World Trade Center Boston & Seaport Hotel, in Boston, Massachusetts.
Proteins are large biological molecules that are present in and vital to all living cells. Proteins comprise a major part of skin, muscles, organs, and glands, and include many substances necessary for the proper functioning of an organism, such as hormones, enzymes, and antibodies. The analysis of protein structure and function ("proteomics") is essential to the development of new drugs, vaccines, and diagnostics.
Proteins are often analyzed using a sophisticated laboratory method called mass spectrometry, which requires that proteins first be broken down into smaller fragments called peptides. This process is often accomplished by placing the protein in a test tube with the enzyme trypsin, and incubating the mixture overnight. During this time, trypsin "digests" the protein into its smaller peptide fragments, which can then be easily identified by the mass spectrometer. This method has been shown to give invaluable information about proteins, their peptide building blocks, the amino acids that make up the peptides, and the nucleic acids (DNA and RNA) that instruct the cell to produce the proteins.
Dr. Alexander Lazarev, Vice President of Research
|SOURCE Pressure BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved